Gene Regulation: From Mechanisms to Disease joint with Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities Organizer(s): Karen Adelman and Patrick Cramer Date: January 26 - 30, 2020
Location: Keystone Resort, Keystone, CO, USAOrganismal development, homeostasis and healthy aging all rely on precise control of gene expression programs. Recent technological advances in structural biology, real-time imaging, and next generation sequencing have shed new light on decades-old questions about gene regulation, and we seek to highlight these advances. This meeting aims to bring together pioneers in cryoEM, single-cell microscopy, single cell sequencing and three-dimensional genome architecture, with leading experts in transcriptional regulation, to seed new collaborations and discoveries. This conference provides an ideal environment to foster interactions between transcriptional biologists and experts in single cell imaging and genomic approaches and spur conversations about how to interweave new techniques for structural biology with our growing appreciation that many critical interactions involve intrinsically disordered domains (which are by definition not well behaved in most structural approaches). Participants will attend sessions that critically evaluate the impact of genome organization on gene expression. The conference will also expose trainees to the best science possible and instill in them the enthusiasm we feel for the future of the field. Finally, pairing of this meeting with Cancer Epigenetics is ideal as the topics are inherently related. This allows our meeting to focus on underlying mechanisms and normal developmental systems, while enabling the audience to attend lectures in gene dysregulation in cancer. We plan two joint sessions to maximize interactions. Scholarship Deadline: October 1 2019 Discounted Abstract Deadline: October 1 2019 Abstract Deadline: October 29 2019 Discounted Registration Deadline: November 26 2019 We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Promega Corporation
We gratefully acknowledge the generous grant for this conference provided by: National Human Genome Research Institute (NHGRI)Grant No. 1R13HG010828-01 Funding for this conference was made possible (in part) by 1R13HG010828-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. |